PTC Therapeutics Inc (NASDAQ: PTCT), a science-driven, global biopharmaceutical company, has completed the acquisition of Censa Pharmaceuticals Inc, a biopharmaceutical company concentrated on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, it was reported on Monday.
The deal is to add CNSA-001 to PTC's range of treatments for rare disorders. The product is a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. The Phase 2 trial evaluating CNSA-001 for PKU met its primary and secondary endpoints in December 2019, and the program is Phase 3 ready.
Stuart W Peltz, PhD, chief executive officer, PTC Therapeutics Inc, said, 'We're thrilled to complete the acquisition of Censa. This acquisition adds a well-established late-stage PKU clinical program to our growing rare disease portfolio. Given PTC's established development and commercial capabilities, we're well-positioned to bring this therapy to patients with unmet medical need expeditiously.'
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval